> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# InflaRx Plans Two 2027 Izicopan Vasculitis Trials, Sees $1.5 - 2.0 Billion Peak Sales Potential
- URL: https://www.bullished.co/inflarx-plans-two-2027-izicopan-vasculitis-trials-sees-1-5-2-0-billion-peak-sales-2eeeb123/
- Published: 2026-11-03T21:54:19.000Z
- Updated: 2026-11-03T21:54:19.000Z
- Description: The company's own research puts peak sales potential at $1.5 - 2.0 billion, and it says €153.3 million in cash lasts through 2029.
- Author: Matteo Parrino
- Tags: SEC Filings, IFRX, Industry: Healthcare

InflaRx, the Jena, Germany-based company that develops drugs blocking the immune protein C5a or its receptor, said Tuesday it intends to start [two Phase 2 trials](https://www.sec.gov/Archives/edgar/data/1708688/000114036126041828/ef20054802%5Fex99-1.htm?ref=bullished.co) of its pill izicopan in ANCA-associated vasculitis (AAV) in 2027, with first data anticipated in 2028\. At its Capital Markets Day, the company also said its own research points to peak sales potential of $1.5 - 2.0 billion.

## Two trials, two different questions

The first study is randomized, double-blind and placebo-controlled, in AAV patients with kidney involvement. Site initiation is expected in early 2027\. It tests two izicopan doses on top of standard care, including rituximab and a steroid taper, with [about 35 patients](https://www.sec.gov/Archives/edgar/data/1708688/000114036126041828/ef20054802%5Fex99-1.htm?ref=bullished.co) per arm, 12 months of treatment and key readouts at 24 weeks. Enrollment is planned to take about 18 months.

The second is an open-label study in newly diagnosed or relapsing patients needing remission-inducing therapy. It uses two stages: a rapid glucocorticoid (steroid) taper first, then, once safety is assessed, a planned complete replacement of the steroid. First data are expected in 2028.

The company said that study draws on a Phase 1/2 trial of BDB-001, an antibody targeting C5a licensed to its Chinese partner Staidson BioPharmaceuticals, in which complete steroid replacement at enrollment produced numerically favorable remission rates against an open-label control arm. InflaRx does not expect running both trials at once to slow enrollment, citing different enrollment criteria and separate centers.

The placebo-controlled design was informed by first interactions with the FDA, the company said, and it continues to look for the fastest route into a registration-stage trial.

## A $1.5 - 2.0 billion estimate, and who made it

InflaRx said its proprietary research indicates izicopan could significantly expand the AAV market, with estimated peak sales potential of $1.5 - 2.0 billion, based on an independent commercial assessment. The company says the pill could offer faster and deeper target inhibition, more convenient dosing and a better safety profile. It reports no safety signals of concern among the 197 people dosed so far.

CEO Niels Riedemann said C5aR inhibition "[has been clinically and commercially validated](https://www.sec.gov/Archives/edgar/data/1708688/000114036126041828/ef20054802%5Fex99-1.htm?ref=bullished.co)," and that izicopan was built to extend that foundation.

## Cash through 2029, and other readouts

Cash, cash equivalents and marketable securities came to €153.3 million on September 30, 2026, which the company expects to fund operations and development through 2029.

Beyond AAV, InflaRx expects initial data from an investigator-initiated pilot study in atypical hemolytic uremic syndrome in the second half of 2027\. It plans a pilot in IgA nephropathy starting in 2027, with early data in 2028\. A pharmacokinetic bridging study in China is expected to report in the first half of 2027\. Staidson's Phase 3 AAV trial of BDB-001 in China has data anticipated in the second half of 2028.

The company also named a seven-member advisory board of vasculitis and kidney-disease experts.

The first scheduled readout is the China pharmacokinetic bridging study, due in the first half of 2027.

### Sources

- [Form 6-K — InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day](https://www.sec.gov/Archives/edgar/data/1708688/000114036126041828/ef20054802%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR